Angiopoietin-1 and Angiopoietin-2 in metabolic disorders: therapeutic strategies to restore the highs and lows of angiogenesis in diabetes. (Q38877104)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27344309%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

review article

1 reference

title

Angiopoietin-1 and Angiopoietin-2 in metabolic disorders: therapeutic strategies to restore the highs and lows of angiogenesis in diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27344309%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27344309%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Mary Anna Venneri

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27344309%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

author name string

D Fiore

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27344309%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

publication date

25 June 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27344309%20AND%20SRC:MED&resulttype=core&format=json

Journal of Endocrinological Investigation

16 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27344309%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27344309%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

page(s)

1235-1246

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27344309%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27344309%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s40618-016-0502-0

16 March 2020

exact match

0 references

cites work

Angiogenesis in life, disease and medicine

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Fundamental Concepts of the Angiogenic Process

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Wound repair and regeneration: mechanisms, signaling, and translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Angiopoietin-1 is essential in mouse vasculature during development and in response to injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Critical role of the TIE2 endothelial cell receptor in the development of definitive hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Akt is a major angiogenic mediator downstream of the Ang1/Tie2 signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Angiopoietin-1 promotes cardiac and skeletal myocyte survival through integrins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

The antiinflammatory endothelial tyrosine kinase Tie2 interacts with a novel nuclear factor-kappaB inhibitor ABIN-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Hepatocyte growth factor mediates angiopoietin-induced smooth muscle cell recruitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Long-term and sustained COMP-Ang1 induces long-lasting vascular enlargement and enhanced blood flow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Angiopoietin-1 protects the adult vasculature against plasma leakage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Sustained improvement in perfusion and flow reserve after temporally separated delivery of vascular endothelial growth factor and angiopoietin-1 plasmid deoxyribonucleic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

VEGF165 and angiopoietin-1 decreased myocardium infarct size through phosphatidylinositol-3 kinase and Bcl-2 pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Coadministration of adenoviral vascular endothelial growth factor and angiopoietin-1 enhances vascularization and reduces ventricular remodeling in the infarcted myocardium of type 1 diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Protective role of COMP-Ang1 in ischemic rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

COMP-Angiopoietin-1 ameliorates surgery-induced ischemic necrosis of the femoral head in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Intracavernous delivery of a designed angiopoietin-1 variant rescues erectile function by enhancing endothelial regeneration in the streptozotocin-induced diabetic mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Peritubular capillary preservation with COMP-angiopoietin-1 decreases ischemia-reperfusion-induced acute kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Angiopoietin-1 overexpression modulates vascular endothelium to facilitate tumor cell dissemination and metastasis establishment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Induction of pulmonary hypertension by an angiopoietin 1/TIE2/serotonin pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Vascular endothelial growth factor-angiopoietin chimera with improved properties for therapeutic angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Different effects of angiopoietin-2 in different vascular beds: new vessels are most sensitive.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

The pathobiology of diabetic complications: a unifying mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Oscillating high glucose enhances oxidative stress and apoptosis in human coronary artery endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Clinical and genetic correlates of circulating angiopoietin-2 and soluble Tie-2 in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Circulating angiopoietin-2 and soluble Tie-2 in type 2 diabetes mellitus: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

High glucose and elevated fatty acids suppress signaling by the endothelium protective ligand angiopoietin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Pancreatic islet production of vascular endothelial growth factor--a is essential for islet vascularization, revascularization, and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Angiopoietin-1 protects myocardial endothelial cell function blunted by angiopoietin-2 and high glucose condition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Expressional regulation of angiopoietin-1 and -2 and the tie-1 and -2 receptor tyrosine kinases during cutaneous wound healing: a comparative study of normal and impaired repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Abnormal regulation of neo-vascularisation in deep partial thickness scalds in rats with diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Angiopoietin-2 levels in glucose intolerance, hypertension, and metabolic syndrome in Asian Indians (Chennai Urban Rural Epidemiology Study-74).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Serum angiopoietin-2 is associated with angiopathy in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Association between interleukin-19 and angiopoietin-2 with vascular complications in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Therapeutic effect of alprostadil in diabetic nephropathy: possible roles of angiopoietin-2 and IL-18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Renoprotective effect of COMP-angiopoietin-1 in db/db mice with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

COMP-angiopoietin-1 recovers molecular biomarkers of neuropathy and improves vascularisation in sciatic nerve of ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

COMP-angiopoietin-1 enhances skeletal muscle blood flow and insulin sensitivity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Angiopoietin-2 is associated with albuminuria and microinflammation in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Urinary angiopoietin-2 is associated with albuminuria in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Tumor Necrosis Factor-Alpha and 8-Hydroxy-2'-Deoxyguanosine are Associated with Elevated Urinary Angiopoietin-2 Level in Type 2 Diabetic Patients with Albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Early systemic microvascular damage in pigs with atherogenic diabetes mellitus coincides with renal angiopoietin dysbalance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Hereditary proteinuria syndromes and mechanisms of proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Blockade of airway inflammation and hyper-responsiveness by an angiopoietin-1 variant, COMP-Ang1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Targeted glomerular angiopoietin-1 therapy for early diabetic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Retinal overexpression of angiopoietin-2 mimics diabetic retinopathy and enhances vascular damages in hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Intravitreal AAV2.COMP-Ang1 Prevents Neurovascular Degeneration in a Murine Model of Diabetic Retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Circulating angiopoietins-1 and -2, angiopoietin receptor Tie-2 and vascular endothelial growth factor-A as biomarkers of acute myocardial infarction: a prospective nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Disruption of Ang-1/Tie-2 signaling contributes to the impaired myocardial vascular maturation and angiogenesis in type II diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Ang-1 gene therapy inhibits hypoxia-inducible factor-1alpha (HIF-1alpha)-prolyl-4-hydroxylase-2, stabilizes HIF-1alpha expression, and normalizes immature vasculature in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Thrombospondin-1 induction in the diabetic myocardium stabilizes the cardiac matrix in addition to promoting vascular rarefaction through angiopoietin-2 upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Additive effect of AAV-mediated angiopoietin-1 and VEGF expression on the therapy of infarcted heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Adenoviral-delivered angiopoietin-1 reduces the infarction and attenuates the progression of cardiac dysfunction in the rat model of acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Overexpression of angiopoietin-2 impairs myocardial angiogenesis and exacerbates cardiac fibrosis in the diabetic db/db mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Synergistically therapeutic effects of VEGF165 and angiopoietin-1 on ischemic rat myocardium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Combination of angiopoietin-1 and vascular endothelial growth factor gene therapy enhances arteriogenesis in the ischemic myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Plasma angiopoietin-1 is lower after ischemic stroke and associated with major disability but not stroke incidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Angiopoietin/Tie2 pathway mediates type 2 diabetes induced vascular damage after cerebral stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

The SUBITO-DE study: sexual dysfunction in newly diagnosed type 2 diabetes male patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Inhibition of Ninjurin 1 restores erectile function through dual angiogenic and neurotrophic effects in the diabetic mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

A mouse model of cavernous nerve injury-induced erectile dysfunction: functional and morphological characterization of the corpus cavernosum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Designed angiopoietin-1 variant, COMP-angiopoietin-1, rescues erectile function through healthy cavernous angiogenesis in a hypercholesterolemic mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

COMP-angiopoietin-1 promotes cavernous angiogenesis in a type 2 diabetic rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

COMP-angiopoietin-1 promotes wound healing through enhanced angiogenesis, lymphangiogenesis, and blood flow in a diabetic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Is glucose control important for prevention of cardiovascular disease in diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

COMP-Ang1: a designed angiopoietin-1 variant with nonleaky angiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Angiopoietin-1 variant, COMP-Ang1 attenuates hydrogen peroxide-induced acute lung injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

COMP-angiopoietin-1 decreases lipopolysaccharide-induced acute kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

A Designed Angiopoietin-1 Variant, Dimeric CMP-Ang1 Activates Tie2 and Stimulates Angiogenesis and Vascular Stabilization in N-glycan Dependent Manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Subretinal AAV2.COMP-Ang1 suppresses choroidal neovascularization and vascular endothelial growth factor in a murine model of age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

A nanobiohybrid complex of recombinant baculovirus and Tat/DNA nanoparticles for delivery of Ang-1 transgene in myocardial infarction therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Scaffolds with covalently immobilized VEGF and Angiopoietin-1 for vascularization of engineered tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Mitotic and antiapoptotic effects of nanoparticles coencapsulating human VEGF and human angiopoietin-1 on vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Acceleration of diabetic wound healing by an angiopoietin peptide mimetic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

A short synthetic peptide inhibits signal transduction, migration and angiogenesis mediated by Tie2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

The Synthetic Tie2 Agonist Peptide Vasculotide Protects Renal Vascular Barrier Function In Experimental Acute Kidney Injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

A human neutralizing antibody specific to Ang-2 inhibits ocular angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Induction of Angiogenesis by a Type III Phosphodiesterase Inhibitor, Cilostazol, Through Activation of Peroxisome Proliferator-Activated Receptor-γ and cAMP Pathways in Vascular Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Therapy of endocrine disease. Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

PDE5 Inhibition Ameliorates Visceral Adiposity Targeting the miR-22/SIRT1 Pathway: Evidence From the CECSID Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Endothelial dysfunction markers as a therapeutic target for Sildenafil treatment and effects on metabolic control in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Chronic Inhibition of PDE5 Limits Pro-Inflammatory Monocyte-Macrophage Polarization in Streptozotocin-Induced Diabetic Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Sildenafil ameliorates long term peripheral neuropathy in type II diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Combination of Injectable Multiple Growth Factor–Releasing Scaffolds and Cell Therapy as an Advanced Modality to Enhance Tissue Neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40618-016-0502-0

Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis

21 January 2018

1 reference

12 December 2020

EphB ligand, ephrinB2, suppresses the VEGF- and angiopoietin 1-induced Ras/mitogen-activated protein kinase pathway in venous endothelial cells

1 reference

12 December 2020

Angiogenesis, arteriogenesis, and diabetes: paradigm reassessed?

1 reference

12 December 2020

Tie-ing the antiinflammatory effect of angiopoietin-1 to inhibition of NF-kappaB

1 reference

12 December 2020

Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors.

1 reference

12 December 2020

Interleukin-19 and angiopoietin-2 can enhance angiogenesis of diabetic complications

1 reference

12 December 2020

Effect of diabetes mellitus on formation of coronary collateral vessels

1 reference

12 December 2020

Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells.

1 reference

12 December 2020

Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway

1 reference

12 December 2020

Increased vascularization in mice overexpressing angiopoietin-1

1 reference

12 December 2020

Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia

1 reference

12 December 2020

Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells

1 reference

12 December 2020

Potential role of soluble angiopoietin-2 and Tie-2 in patients with inflammatory bowel disease

1 reference

12 December 2020

Impaired pericyte recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 overexpression.

1 reference

12 December 2020

1 reference

12 December 2020

Angiopoietin-2 impairs revascularization after limb ischemia

1 reference

12 December 2020

Chronic Inhibition of cGMP Phosphodiesterase 5A Improves Diabetic Cardiomyopathy

1 reference

12 December 2020

Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFβ1 in diabetic eyes undergoing vitrectomy

1 reference

12 December 2020